Variational AI will participate in BIO-Europe 2026, one of the world’s leading partnering conferences for the biotechnology and pharmaceutical industries.
The event brings together biotech companies, pharmaceutical firms, investors, and technology innovators from across the global life sciences ecosystem to explore partnerships, licensing opportunities, and new approaches to advancing therapeutic development.
Meet the Variational AI Team in Germany
Members of the Variational AI team will be attending BIO-Europe 2026 to connect with investors and potential partners interested in AI-driven drug discovery and generative molecular design.
If you are attending the conference and would like to learn more about Variational AI’s technology platform and collaboration opportunities, we would welcome the opportunity to meet.
Handol Kim,
CEO
Pete Guzzo,
EVP & Head of Drug Discovery
Valentin Beuchillot,
Senior Manager, BD & Marketing
A Global Forum for Biopharma Partnerships
BIO-Europe is the largest and longest-running biotechnology partnering conference in Europe, convening thousands of industry leaders each year to accelerate collaboration across the life sciences sector.
The conference is designed to facilitate strategic connections through a combination of structured one-to-one meetings, company presentations, panel discussions, and networking events. These interactions support partnerships across discovery, development, and commercialization of new therapeutics and technologies.
With more than 5,000 attendees from over 60 countries, BIO-Europe has become a key meeting point for companies seeking to build collaborations and investment relationships within the global biotechnology ecosystem.